355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)

Authors :: Kevin Kalinsky
Jennifer L. Schutzman
S. Loibl
Dejan Juric
S-A. Im
Guiyuan Lei
Komal Jhaveri
Peter Schmid
N. Turner
E. Thanopoulou
Cristina Saura
Katie Hutchinson
Thomas J Stout
Sherene Loi
Source :: Annals of Oncology. 31:S391-S392
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Fulvestrant
business.industry
Mutant
Locally advanced
Hematology
Palbociclib
medicine.disease
Placebo
Metastatic breast cancer
Hormone receptor
Internal medicine
medicine
In patient
business
medicine.drug

Tools